About 8th Antifibrotic Drug Development Summit 2024

The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. As the focus expands to other fibrotic diseases such as fibrosing IBD, cardiac fibrosis, and kidney fibrosis, the 8th Antifibrotic Drug Development Summit stands as the definitive forum for innovation.

Over the course of three days, this summit brings together key decision-makers to explore the latest breakthroughs in the field. From discovery and novel targets to preclinical models and early-stage clinical trials, attendees will gain unparalleled insights to accelerate the development of antifibrotic therapies.